The global Generic Drugs market is projected to grow at a CAGR of 5.3% by 2034
The Generic Drugs Market Report 2024-2034: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.
Rising Geriatric Population and Cost Affordability of Generic Drugs Projected to Boost Industry Growth
The generic drugs market is expected to be significantly driven by key factors such as the rising geriatric population and the cost affordability and effectiveness of generic medications. As the global demographic structure shifts towards an aging population, the prevalence of chronic diseases increases, necessitating long-term treatments. Generic drugs, known for their therapeutic equivalence to brand-name counterparts and cost-effectiveness, emerge as crucial solutions to meet the healthcare needs of the elderly. The affordability of generic drugs aligns with the economic constraints often faced by seniors, fostering widespread adoption. Governments and healthcare systems, recognizing the financial advantages and accessibility benefits of generic drugs, are likely to support policies and initiatives that further propel market growth. The combination of a growing elderly population seeking affordable treatments and the proven effectiveness of generic drugs positions this market to play a pivotal role in addressing healthcare challenges and ensuring broader access to essential medications.
Adverse Effects Associated with Drugs Likely to Challenge Market Growth
Adverse effects associated with drugs are anticipated to pose a substantial challenge for the generic drugs market. While generic medications aim to replicate the therapeutic effects of their brand-name counterparts, the one-size-fits-all approach may not adequately address individual variations in patient response. This lack of individualized formulations raises concerns about potential adverse reactions, as patients may experience side effects or inadequate therapeutic responses. Variability in bioavailability among generic drugs further complicates the scenario, potentially leading to variations in drug concentration levels and subsequent adverse effects. Moreover, differences in inactive ingredients between generic and brand-name drugs may impact tolerability, especially for individuals with allergies or sensitivities, creating a need for standardized formulations. The limited post-market surveillance for generic drugs compared to brand-name counterparts raises challenges in timely identification and management of adverse effects, impacting consumer confidence. Addressing these adverse effects associated with generic drugs requires enhanced regulatory measures, rigorous quality control, and a focus on individualized medicine to ensure the sustained growth and success of the generic drugs market.
What Questions Should You Ask before Buying a Market Research Report?
How is the generic drugs market evolving?
What is driving and restraining the generic drugs market?
How will each generic drugs submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?
How will the market shares for each generic drugs submarket develop from 2024 to 2034?
What will be the main driver for the overall market from 2024 to 2034?
Will leading generic drugs markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
How will the market shares of the national markets change by 2034 and which geographical region will lead the market in 2034?
Who are the leading players and what are their prospects over the forecast period?
How will the industry evolve during the period between 2024 and 2034? What are the implications of generic drugs projects taking place now and over the next 10 years?
Is there a greater need for product commercialisation to further scale the generic drugs market?
Where is the generic drugs market heading and how can you ensure you are at the forefront of the market?
What are the best investment options for new product and service lines?
What are the key prospects for moving companies into a new growth path and C-suite?
You need to discover how this will impact the Generic Drugs Market today, and over the next 10 years:
Our 357-page report provides 133 tables, 223 charts/graphs exclusively to you.
The report highlights key lucrative areas in the industry so you can target them - NOW.
It contains in-depth analysis of global, regional and national sales and growth.
It highlights for you the key successful trends, changes and revenue projections made by your competitors.
This report tells you TODAY how the Generic Drugs Market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.
Forecasts to 2034 and other analyses reveal commercial prospects
In addition to revenue forecasting to 2034, our new study provides you with recent results, growth rates, and market shares.
You will find original analyses, with business outlooks and developments.
Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising generic drugs prices and recent developments.
This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, "V", "L", "W" and "U" are discussed in this report.
Segments Covered in the Report
Type
Simple Generics
Specialty Generics
Biosimilars
Route of Administration
Oral
Parenteral
Topical
Others
Indication
Central Nervous System (CNS)
Oncology
Infectious Diseases
Cardiovascular Diseases
Gastrointestinal Diseases
Musculoskeletal Diseases
Others
Drug Class
Antibiotics
Antihistamines
Analgesics
Antihypertensive
Antidiabetic
Antipyretic
Others
Prescription Type
Prescription Generics
Over-the-Counter (OTC) Generics
Distribution Channel
Retail Pharmacies
Hospital Pharmacies
Online Pharmacies
Others
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 20 leading national markets:
North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
Rest of Europe
Asia Pacific
China
Japan
India
Australia
South Korea
Rest of Asia Pacific
Latin America
Brazil
Argentina
Rest of Latin America
MEA
GCC Countries
South Africa
Rest of MEA
The report also includes profiles and for some of the leading companies in the Generic Drugs Market, 2024 to 2034, with a focus on this segment of these companies' operations.
Leading companies and the potential for market growth
Alkem Laboratories Ltd.
Amneal Pharmaceuticals LLC
Aurobindo Pharma
Biocon
Cipla Inc.
Dr. Reddy's Laboratories Ltd.
Endo International plc
Lupin
Novartis AG
Sun Pharmaceuticals Industries Ltd.
Teva Pharmaceutical Industries Ltd.
Torrent Pharmaceuticals Ltd.
Viatris Inc.
Overall world revenue for Generic Drugs Market, 2024 to 2034 in terms of value the market will surpass US$450.0 billion in 2024, our work calculates. We predict strong revenue growth through to 2034. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How will the Generic Drugs Market, 2024 to 2034 report help you?
In summary, our 350+ page report provides you with the following knowledge:
Revenue forecasts to 2034 for Generic Drugs Market, 2024 to 2034, with forecasts for type, prescription type, indication, drug class, route of administration, distribution channel, each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.
Revenue forecasts to 2034 for five regional and 20 key national markets - See forecasts for the Generic Drugs Market, 2024 to 2034 market in North America, Europe, Asia-Pacific, Latin America and MEA. Also forecasted is the market in the US, Canada, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
Prospects for established firms and those seeking to enter the market - including company profiles for 13 of the major companies involved in the Generic Drugs Market, 2024 to 2034.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.
Information found nowhere else
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain's study is for everybody needing commercial analyses for the Generic Drugs Market, 2024 to 2034, market-leading companies. You will find data, trends and predictions.
Table of Contents
1 Report Overview
- 1.1 Objectives of the Study
- 1.2 Introduction to Generic Drugs Market
- 1.3 What This Report Delivers
- 1.4 Why You Should Read This Report
- 1.5 Key Questions Answered by This Analytical Report
- 1.6 Who is This Report for?
- 1.7 Methodology
- 1.7.1 Market Definitions
- 1.7.2 Market Evaluation & Forecasting Methodology
- 1.7.3 Data Validation
- 1.7.3.1 Primary Research
- 1.7.3.2 Secondary Research
- 1.8 Frequently Asked Questions (FAQs)
- 1.9 Associated Visiongain Reports
- 1.10 About Visiongain
2 Executive Summary
3 Market Overview
- 3.1 Key Findings
- 3.2 Market Dynamics
- 3.2.1 Market Driving Factors
- 3.2.1.1 Cost Affordability and Effectiveness of Generic Drugs
- 3.2.1.2 Strategic Partnerships among Generic Drugs Manufacturers
- 3.2.1.3 Rise in Geriatric Population
- 3.2.1.4 Rise in Chronic Disorders
- 3.2.1.5 Rising Government Initiative to Promote Generic Drugs
- 3.2.2 Market Restraining Factors
- 3.2.2.1 Stringent Government Regulations
- 3.2.2.2 Brand Loyalty
- 3.2.2.3 Intellectual Property Lawsuits and Patent Disputes
- 3.2.2.4 Adverse Effects Associated with the Drugs
- 3.2.3 Market Opportunities
- 3.2.3.1 Patent Expiration of Blockbuster Drugs in this Decade
- 3.2.3.2 Growth of Biologics and Biosimilars
- 3.3 COVID-19 Impact Analysis
- 3.4 Porter's Five Forces Analysis
- 3.4.1 Bargaining Power of Suppliers
- 3.4.2 Bargaining Power of Buyers
- 3.4.3 Competitive Rivalry
- 3.4.4 Threat from Substitutes
- 3.4.5 Threat of New Entrants
- 3.5 PEST Analysis
- 3.5.1 Political
- 3.5.2 Economical
- 3.5.3 Social
- 3.5.4 Technological
4 Generic Drugs Market Analysis by Type
- 4.1 Key Findings
- 4.2 Type Segment: Market Attractiveness Index
- 4.3 Generic Drugs Market Size Estimation and Forecast by Type
- 4.4 Simple Generics
- 4.4.1 Market Size by Region, 2024-2034 (US$ Billion)
- 4.4.2 Market Share by Region, 2024 & 2034 (%)
- 4.5 Specialty Generics
- 4.5.1 Market Size by Region, 2024-2034 (US$ Billion)
- 4.5.2 Market Share by Region, 2024 & 2034 (%)
- 4.6 Biosimilars
- 4.6.1 Market Size by Region, 2024-2034 (US$ Billion)
- 4.6.2 Market Share by Region, 2024 & 2034 (%)
5 Generic Drugs Market Analysis by Prescription Type
- 5.1 Key Findings
- 5.2 Prescription Type Segment: Market Attractiveness Index
- 5.4 Generic Drugs Market Size Estimation and Forecast by Prescription Type
- 5.5 Prescription Generics
- 5.5.1 Market Size by Region, 2024-2034 (US$ Billion)
- 5.5.2 Market Share by Region, 2024 & 2034 (%)
- 5.6 Over-the-Counter (OTC) Generics
- 5.6.1 Market Size by Region, 2024-2034 (US$ Billion)
- 5.6.2 Market Share by Region, 2024 & 2034 (%)
6 Generic Drugs Market Analysis by Indication
- 6.1 Key Findings
- 6.2 Indication Segment: Market Attractiveness Index
- 6.4 Generic Drugs Market Size Estimation and Forecast by Indication
- 6.5 Central Nervous System (CNS)
- 6.5.1 Market Size by Region, 2024-2034 (US$ Billion)
- 6.5.2 Market Share by Region, 2024 & 2034 (%)
- 6.6 Oncology
- 6.6.1 Market Size by Region, 2024-2034 (US$ Billion)
- 6.6.2 Market Share by Region, 2024 & 2034 (%)
- 6.7 Infectious Diseases
- 6.7.1 Market Size by Region, 2024-2034 (US$ Billion)
- 6.7.2 Market Share by Region, 2024 & 2034 (%)
- 6.8 Cardiovascular Diseases
- 6.8.1 Market Size by Region, 2024-2034 (US$ Billion)
- 6.8.2 Market Share by Region, 2024 & 2034 (%)
- 6.9 Gastrointestinal Diseases
- 6.9.1 Market Size by Region, 2024-2034 (US$ Billion)
- 6.9.2 Market Share by Region, 2024 & 2034 (%)
- 6.10 Musculoskeletal Diseases
- 6.10.1 Market Size by Region, 2024-2034 (US$ Billion)
- 6.10.2 Market Share by Region, 2024 & 2034 (%)
- 6.11 Others
- 6.11.1 Market Size by Region, 2024-2034 (US$ Billion)
- 6.11.2 Market Share by Region, 2024 & 2034 (%)
7 Generic Drugs Market Analysis by Drug Class
- 7.1 Key Findings
- 7.2 Drug Class Segment: Market Attractiveness Index
- 7.4 Generic Drugs Market Size Estimation and Forecast by Drug Class
- 7.5 Antibiotics
- 7.5.1 Market Size by Region, 2024-2034 (US$ Billion)
- 7.5.2 Market Share by Region, 2024 & 2034 (%)
- 7.6 Antihistamines
- 7.6.1 Market Size by Region, 2024-2034 (US$ Billion)
- 7.6.2 Market Share by Region, 2024 & 2034 (%)
- 7.7 Analgesics
- 7.7.1 Market Size by Region, 2024-2034 (US$ Billion)
- 7.7.2 Market Share by Region, 2024 & 2034 (%)
- 7.8 Antihypertensive
- 7.8.1 Market Size by Region, 2024-2034 (US$ Billion)
- 7.8.2 Market Share by Region, 2024 & 2034 (%)
- 7.9 Antidiabetic
- 7.9.1 Market Size by Region, 2024-2034 (US$ Billion)
- 7.9.2 Market Share by Region, 2024 & 2034 (%)
- 7.10 Antipyretic
- 7.10.1 Market Size by Region, 2024-2034 (US$ Billion)
- 7.10.2 Market Share by Region, 2024 & 2034 (%)
- 7.11 Others
- 7.11.1 Market Size by Region, 2024-2034 (US$ Billion)
- 7.11.2 Market Share by Region, 2024 & 2034 (%)
8 Generic Drugs Market Analysis by Route of Administration
- 8.1 Key Findings
- 8.2 Route of Administration Segment: Market Attractiveness Index
- 8.4 Generic Drugs Market Size Estimation and Forecast by Route of Administration
- 8.5 Oral
- 8.5.1 Market Size by Region, 2024-2034 (US$ Billion)
- 8.5.2 Market Share by Region, 2024 & 2034 (%)
- 8.6 Parenteral
- 8.6.1 Market Size by Region, 2024-2034 (US$ Billion)
- 8.6.2 Market Share by Region, 2024 & 2034 (%)
- 8.7 Topical
- 8.7.1 Market Size by Region, 2024-2034 (US$ Billion)
- 8.7.2 Market Share by Region, 2024 & 2034 (%)
- 8.8 Others
- 8.8.1 Market Size by Region, 2024-2034 (US$ Billion)
- 8.8.2 Market Share by Region, 2024 & 2034 (%)
9 Generic Drugs Market Analysis by Distribution Channel
- 9.1 Key Findings
- 9.2 Distribution Channel Segment: Market Attractiveness Index
- 9.4 Generic Drugs Market Size Estimation and Forecast by Distribution Channel
- 9.5 Hospital Pharmacies
- 9.5.1 Market Size by Region, 2024-2034 (US$ Billion)
- 9.5.2 Market Share by Region, 2024 & 2034 (%)
- 9.6 Retail Pharmacies
- 9.6.1 Market Size by Region, 2024-2034 (US$ Billion)
- 9.6.2 Market Share by Region, 2024 & 2034 (%)
- 9.7 Online Pharmacies
- 9.7.1 Market Size by Region, 2024-2034 (US$ Billion)
- 9.7.2 Market Share by Region, 2024 & 2034 (%)
- 9.8 Others
- 9.8.1 Market Size by Region, 2024-2034 (US$ Billion)
- 9.8.2 Market Share by Region, 2024 & 2034 (%)
10 Generic Drugs Market Analysis by Region
- 10.1 Key Findings
- 10.3 Regional Market Size Estimation and Forecast
11 North America Generic Drugs Market Analysis
- 11.1 Key Findings
- 11.2 North America Generic Drugs Market Attractiveness Index
- 11.3 North America Generic Drugs Market by Country, 2024, 2029 & 2034 (US$ Billion)
- 11.4 North America Generic Drugs Market Size Estimation and Forecast by Country
- 11.5 North America Generic Drugs Market Size Estimation and Forecast by Type
- 11.6 North America Generic Drugs Market Size Estimation and Forecast by Route of Administration
- 11.7 North America Generic Drugs Market Size Estimation and Forecast by Indication
- 11.8 North America Generic Drugs Market Size Estimation and Forecast by Drug Class
- 11.9 North America Generic Drugs Market Size Estimation and Forecast by Prescription Type
- 11.10 North America Generic Drugs Market Size Estimation and Forecast by Distribution Channel
- 11.11 U.S. Generic Drugs Market Analysis
- 11.12 Canada Generic Drugs Market Analysis
12 Europe Generic Drugs Market Analysis
- 12.1 Key Findings
- 12.2 Europe Generic Drugs Market Attractiveness Index
- 12.3 Europe Generic Drugs Market by Country, 2024, 2029 & 2034 (US$ Billion)
- 12.4 Europe Generic Drugs Market Size Estimation and Forecast by Country
- 12.5 Europe Generic Drugs Market Size Estimation and Forecast by Type
- 12.6 Europe Generic Drugs Market Size Estimation and Forecast by Route of Administration
- 12.7 Europe Generic Drugs Market Size Estimation and Forecast by Indication
- 12.8 Europe Generic Drugs Market Size Estimation and Forecast by Drug Class
- 12.9 Europe Generic Drugs Market Size Estimation and Forecast by Prescription Type
- 12.10 Europe Generic Drugs Market Size Estimation and Forecast by Distribution Channel
- 12.11 Germany Generic Drugs Market Analysis
- 12.12 UK Generic Drugs Market Analysis
- 12.13 France Generic Drugs Market Analysis
- 12.14 Italy Generic Drugs Market Analysis
- 12.15 Spain Generic Drugs Market Analysis
- 12.16 Rest of Europe Generic Drugs Market Analysis
13 Asia Pacific Generic Drugs Market Analysis
- 13.1 Key Findings
- 13.2 Asia Pacific Generic Drugs Market Attractiveness Index
- 13.3 Asia Pacific Generic Drugs Market by Country, 2024, 2029 & 2034 (US$ Billion)
- 13.4 Asia Pacific Generic Drugs Market Size Estimation and Forecast by Country
- 13.5 Asia Pacific Generic Drugs Market Size Estimation and Forecast by Type
- 13.6 Asia Pacific Generic Drugs Market Size Estimation and Forecast by Route of Administration
- 13.7 Asia Pacific Generic Drugs Market Size Estimation and Forecast by Indication
- 13.8 Asia Pacific Generic Drugs Market Size Estimation and Forecast by Drug Class
- 13.9 Asia Pacific Generic Drugs Market Size Estimation and Forecast by Prescription Type
- 13.10 Asia Pacific Generic Drugs Market Size Estimation and Forecast by Distribution Channel
- 13.11 Japan Generic Drugs Market Analysis
- 13.12 China Generic Drugs Market Analysis
- 13.13 India Generic Drugs Market Analysis
- 13.14 Australia Generic Drugs Market Analysis
- 13.15 South Korea Generic Drugs Market Analysis
- 13.16 Rest of Asia Pacific Generic Drugs Market Analysis
14 Latin America Generic Drugs Market Analysis
- 14.1 Key Findings
- 14.2 Latin America Generic Drugs Market Attractiveness Index
- 14.3 Latin America Generic Drugs Market by Country, 2024, 2029 & 2034 (US$ Billion)
- 14.4 Latin America Generic Drugs Market Size Estimation and Forecast by Country
- 14.5 Latin America Generic Drugs Market Size Estimation and Forecast by Type
- 14.6 Latin America Generic Drugs Market Size Estimation and Forecast by Route of Administration
- 14.7 Latin America Generic Drugs Market Size Estimation and Forecast by Indication
- 14.8 Latin America Generic Drugs Market Size Estimation and Forecast by Drug Class
- 14.9 Latin America Generic Drugs Market Size Estimation and Forecast by Prescription Type
- 14.10 Latin America Generic Drugs Market Size Estimation and Forecast by Distribution Channel
- 14.11 Brazil Generic Drugs Market Analysis
- 14.12 Argentina Generic Drugs Market Analysis
- 14.13 Rest of Latin America Generic Drugs Market Analysis
15 MEA Generic Drugs Market Analysis
- 15.1 Key Findings
- 15.2 MEA Generic Drugs Market Attractiveness Index
- 15.3 MEA Generic Drugs Market by Country, 2024, 2029 & 2034 (US$ Billion)
- 15.4 MEA Generic Drugs Market Size Estimation and Forecast by Country
- 15.5 MEA Generic Drugs Market Size Estimation and Forecast by Type
- 15.6 MEA Generic Drugs Market Size Estimation and Forecast by Route of Administration
- 15.7 MEA Generic Drugs Market Size Estimation and Forecast by Indication
- 15.8 MEA Generic Drugs Market Size Estimation and Forecast by Drug Class
- 15.9 MEA Generic Drugs Market Size Estimation and Forecast by Prescription Type
- 15.10 MEA Generic Drugs Market Size Estimation and Forecast by Distribution Channel
- 15.11 GCC Generic Drugs Market Analysis
- 15.12 South Africa Generic Drugs Market Analysis
- 15.13 Rest of MEA Generic Drugs Market Analysis
16 Company Profiles
- 16.1 Competitive Landscape, 2023
- 16.2 Novartis AG
- 16.2.1 Company Snapshot
- 16.2.2 Company Overview
- 16.2.3 Financial Analysis
- 16.2.3.1 Net Revenue, 2018-2022
- 16.2.3.2 Regional Market Shares, 2022
- 16.2.3.3 R&D Expense, 2018-2022
- 16.2.5 Product Benchmarking
- 16.2.6 Strategic Outlook
- 16.3 Teva Pharmaceutical Industries Ltd.
- 16.3.1 Company Snapshot
- 16.3.2 Company Overview
- 16.3.3 Financial Analysis
- 16.3.3.1 Revenue, 2018-2022
- 16.3.3.2 Regional Market Shares, 2022
- 16.3.3.3 R&D Expense, 2018-2022
- 16.3.5 Product Benchmarking
- 16.3.6 Strategic Outlook
- 16.4 Viatris Inc.
- 16.4.1 Company Snapshot
- 16.4.2 Company Overview
- 16.4.3 Financial Analysis
- 16.4.3.1 Revenue, 2018-2022
- 16.4.3.2 Regional Market Shares, 2022
- 16.4.3.3 R&D Expense, 2018-2022
- 16.4.5 Product Benchmarking
- 16.4.6 Strategic Outlook
- 16.5 Lupin
- 16.5.1 Company Snapshot
- 16.5.2 Company Overview
- 16.5.3 Financial Analysis
- 16.5.3.1 Revenue, 2018-2022
- 16.5.3.2 R&D Expense, 2018-2022
- 16.5.5 Product Benchmarking
- 16.5.6 Strategic Outlook
- 16.6 Alkem Laboratories Ltd.
- 16.6.1 Company Snapshot
- 16.6.2 Company Overview
- 16.6.3 Financial Analysis
- 16.6.3.1 Net Revenue, 2018-2022
- 16.6.3.2 Regional Market Shares, 2022
- 16.6.3.3 R&D Expense, 2018-2022
- 16.6.4 Product Benchmarking
- 16.6.5 Strategic Outlook
- 16.7 Cipla Inc.
- 16.7.1 Company Snapshot
- 16.7.2 Company Overview
- 16.7.3 Financial Analysis
- 16.7.3.1 Revenue, 2018-2022
- 16.7.3.2 Regional Market Shares, 2022
- 16.7.3.3 R&D Expense, 2018-2022
- 16.7.5 Product Benchmarking
- 16.7.6 Strategic Outlook
- 16.8 Biocon
- 16.8.1 Company Snapshot
- 16.8.2 Company Overview
- 16.8.3 Financial Analysis
- 16.8.3.1 Revenue, 2018-2022
- 16.8.3.2 Segmental Market Shares, 2022
- 16.8.3.3 R&D Expense, 2018-2022
- 16.8.5 Product Benchmarking
- 16.8.6 Strategic Outlook
- 16.9 Aurobindo Pharma
- 16.9.1 Company Snapshot
- 16.9.2 Company Overview
- 16.9.3 Financial Analysis
- 16.9.3.1 Revenue, 2018-2022
- 16.9.4 Product Benchmarking
- 16.9.5 Strategic Outlook
- 16.10 Endo International plc
- 16.10.1 Company Snapshot
- 16.10.2 Company Overview
- 16.10.3 Financial Analysis
- 16.10.3.1 Revenue, 2018-2022
- 16.10.3.2 R&D Expense, 2018-2022
- 16.10.4 Product Benchmarking
- 16.10.5 Strategic Outlook
- 16.11 Torrent Pharmaceuticals Ltd.
- 16.11.1 Company Snapshot
- 16.11.2 Company Overview
- 16.11.3 Financial Analysis
- 16.11.3.1 Revenue, 2018-2022
- 16.11.3.2 Regional Market Shares, 2022
- 16.11.4 Product Benchmarking
- 16.12 Amneal Pharmaceuticals LLC
- 16.12.1 Company Snapshot
- 16.12.2 Company Overview
- 16.12.3 Financial Analysis
- 16.12.3.1 Revenue, 2018-2022
- 16.12.3.2 R&D Expense, 2018-2022
- 16.12.4 Product Benchmarking
- 16.12.5 Strategic Outlook
- 16.13 Dr. Reddy's Laboratories Ltd.
- 16.13.1 Company Snapshot
- 16.13.2 Company Overview
- 16.13.3 Financial Analysis
- 16.13.3.1 Revenue, 2018-2022
- 16.13.3.2 Regional Market Shares, 2022
- 16.13.3.3 R&D Expense, 2018-2022
- 16.13.4 Product Benchmarking
- 16.13.5 Strategic Outlook
- 16.14 Sun Pharmaceutical Industries Ltd.
- 16.14.1 Company Snapshot
- 16.14.2 Company Overview
- 16.14.3 Financial Analysis
- 16.14.3.1 Revenue, 2018-2022
- 16.14.3.2 R&D Expense, 2018-2022
- 16.14.4 Product Benchmarking
- 16.14.5 Strategic Outlook
17 Conclusion and Recommendations
- 17.1 Concluding Remarks from Visiongain
- 17.2 Recommendations for Market Players
